Company: SINT
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021930
Chunk: 1

Company: Sintx Technologies, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 1
---
-term human implantation. Other biomaterials
are based on bone grafts, metal alloys, and polymers- all of which have well-known practical limitations and disadvantages. In contrast,
silicon nitride has a legacy of success in the most demanding and extreme industrial environments. Bacterial infection of any biomaterial
implants is always a concern. SINTX silicon nitride has been shown to be resistant to bacterial colonization and biofilm formation, making
it antibacterial. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease
of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, all of which claims are validated in our
large and growing inventory of peer-reviewed, published literature reports. We believe that our versatile silicon nitride manufacturing
expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.

Antipathogenic
Applications: Today, there is a global need to improve protection against pathogens in everyday life. SINTX believes that by incorporating
its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound
care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and disease.
The discovery in 2020 that SINTX silicon nitride inactivates SARS-CoV-2, the virus which causes the disease COVID-19, has opened new
markets and applications for our material. We presently manufacture advanced ceramic powders and components in our manufacturing facilities
based in Salt Lake City, Utah.

The
SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO 9001:2015, ISO 13485:2016
certified, and ASD9100D certified. The Company’s products are primarily sold in the United States.

Basis
of Presentation

These
unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States
Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company.

SEC
rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared
in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading.
In the opinion of management, these financial statements